According to a press release from Natco, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Natco is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients. "Compassionate use" approval is given for investigational drugs so that a patient with an immediately life-threatening condition can gain access to the drug. CDSCO is responsible for approval of drugs, conduct of clinical trials, laying down the standards for drugs, control over the quality of imported drugs in the country and coordination of the activities of state drug control organisations. Meanwhile, India reported 3,52,991 Covid-19 cases in the last 24 hours, taking the cumulative caseload to 1,73,13,163, said the Union health ministry on Monday morning.

Source: Mint April 26, 2021 04:43 UTC